Why Everyone Takes Ozempic: GLP-1 Trend & Genetic Factors

Last reviewed: May 16, 2026

Last updated: May 16, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

GLP-1 receptor agonists, including semaglutide and tirzepatide, have become one of the fastest-adopted medication classes in recent years, driven by clinical efficacy, media attention, and off-label use for weight management. The trend reflects genuine medical benefit: clinical trials show 15–22% weight loss in patients with obesity when combined with lifestyle modification.

However, not every patient responds identically to these medications, and individual differences in genetics, metabolic health, and baseline physiology significantly influence outcomes. PlexusDx approaches GLP-1 therapy through a precision-wellness lens, examining how biomarkers and genetic predispositions can help contextualize medication choices and support more personalized healthcare conversations.

The Clinical Evidence Behind GLP-1 Adoption

Semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) activate GLP-1 and GIP receptors, slowing gastric emptying and enhancing satiety signals. Multiple randomized controlled trials, including STEP and SUMO studies, demonstrated sustained weight loss and cardiovascular benefits in patients with obesity or type 2 diabetes.

Beyond weight reduction, these medications show cardioprotective effects, improved glycemic control, and reduced cardiovascular event risk in certain populations. This evidence base—coupled with lifestyle modifications—has made GLP-1 therapy a standard option for millions of patients globally, fueling the current surge in adoption and media visibility.

Why Individual Response Varies: Genetics, Metabolism, and Biomarkers

Despite similar study protocols, patients show heterogeneous responses to GLP-1 medications. Approximately 20–30% of trial participants experience minimal weight loss, while others achieve maximal benefit. Genetic variation in GLP-1 receptor (GLP1R) function, appetite-regulating circuits, and metabolic capacity directly influences medication effectiveness and tolerability.

Baseline biomarkers—including insulin resistance (HOMA-IR), fasting glucose, lipid profiles, and inflammatory markers—correlate with both medication response and side-effect burden. Understanding these individual factors allows providers to contextualize treatment expectations and optimize dosing protocols tailored to each patient's metabolic signature.

Factor	Key Information
GLP1R rs6923761 Variant	Common genetic variant affecting GLP-1 receptor sensitivity and medication response potential
GIPR rs1800437 Polymorphism	Influences GIP receptor function; relevant for dual GLP-1/GIP agonists like tirzepatide
FTO rs9939609 SNP	Associated with baseline appetite regulation and fat mass predisposition
MC4R rs17782313 Variant	Melanocortin pathway marker; relates to hunger signaling and satiety response

Hype vs. Healthcare: Understanding the Trend Critically

Media coverage and celebrity endorsements have accelerated GLP-1 visibility, sometimes overshadowing clinical guidelines and appropriate patient selection. Weight loss alone is not the only indicator of therapeutic success; metabolic improvement, cardiovascular risk reduction, and quality-of-life sustainability matter equally for long-term health outcomes.

Responsible prescribing requires careful assessment of baseline health status, contraindications (personal or family history of medullary thyroid cancer, severe pancreatitis), medication interactions, and realistic outcome expectations. GLP-1 therapy is most effective when integrated with sustainable dietary changes, physical activity, and behavioral support—not as a standalone intervention.

Who Benefits Most and Safety Considerations

GLP-1 medications are indicated for adults with type 2 diabetes, obesity (BMI ≥30), or overweight with comorbidities (hypertension, dyslipidemia, cardiovascular disease). Off-label use in normoglycemic individuals remains controversial and should only occur under qualified provider supervision with clear therapeutic rationale and informed consent.

Common side effects include nausea, vomiting, constipation, and abdominal discomfort, particularly during dose escalation. Serious but rare risks include acute pancreatitis, gallbladder complications, and retinopathy changes in diabetic patients. Medical supervision throughout initiation and titration is essential to monitor tolerability, efficacy, and safety outcomes.

How PlexusDx Supports a More Personalized Approach

PlexusDx's Precision Peptide Genetic Test examines key variants in GLP-1 and GIP receptor pathways, as well as appetite-regulation genes like FTO and MC4R. These genetic predispositions may help provide context for how an individual's physiology might theoretically respond to GLP-1 therapy, supporting more nuanced conversations with healthcare providers about medication choice and dosing strategy.

The genetic test does not predict exact medication response or guarantee outcomes; rather, it reveals predispositions in peptide-signaling pathways that influence appetite, satiety, and metabolic regulation. When interpreted alongside clinical assessment—baseline weight, metabolic labs, medical history, and lifestyle factors—genetic insights can support a more personalized treatment framework.

Understanding your genetic predispositions in GLP-1 and GIP pathways can support more informed conversations with your healthcare provider about whether GLP-1 therapy, compounded or otherwise, aligns with your health goals. Combined with biomarker assessment and clinical judgment, genetic context helps shift the focus from population-wide trends to truly individualized medicine.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month, or $298 standalone) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Oral starts at $279/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.